On July 20, 2023 Nusano, Inc., a company working to stabilize and enable the production of cancer-fighting radioisotopes, reported participation in two conferences in July 2023 (Press release, Nusano, JUL 20, 2023, View Source [SID1234633335]). Nusano CEO Chris Lowe will present an overview of the company’s breakthrough radioisotope production platform at the 2nd Annual Targeted Radiopharmaceuticals Summit on July 26 in Boston. Nusano is also presenting two abstracts in oral presentations at the 11th International Conference on Isotopes, in Saskatoon, Saskatchewan, Canada on July 26 and 27.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additional presentation details:

2ND ANNUAL TARGETED RADIOPHARMACEUTICALS SUMMIT (BOSTON)
TITLE: Supplying the Fight Against Cancer: Nusano’s Breakthrough Radioisotope Production Platform
WHO: Chris Lowe, CEO
SESSION: Targeted Radiopharmaceuticals in the US: The Past, the Present & the Future
WHEN: Wednesday, July 26, 2023 at 10:00 AM EDT

11TH INTERNATIONAL CONFERENCE ON ISOTOPES (SASKATOON, SASK.)
ABSTRACT: Nusano Targetry for the Production of Medical Isotopes
WHO: Greg Moffitt, PhD, Director of Target Development
SESSION: Accelerator Produced Radioisotopes
WHEN: Wednesday, July 26, 2023, 3:00 PM – 4:30 PM CST*

ABSTRACT: Alpha Production Routes for Medical Radioisotopes
WHO: Richard Sisson, Targetry Nuclear Engineer
SESSION: Accelerator Produced Radioisotopes II
WHEN: Thursday, July 27, 2023, 9:50 AM – 11:30 AM CST*
* Concurrent session presentations of 15 minutes, with a question-and-answer period at the end of the session.